EC144 Is a Potent Inhibitor of the Heat Shock Protein 90
Authors:
- 31 August 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (17) , 7786-7795
Abstract
Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90α binding assay (IC50 = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice.Keywords
This publication has 41 references indexed in Scilit:
- The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor ActivitiesIn VitroandIn VivoMolecular Cancer Therapeutics, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyBritish Journal of Haematology, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's diseaseProgress in Neurobiology, 2011
- Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800Molecular Cancer Therapeutics, 2010
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsProceedings of the National Academy of Sciences, 2009
- Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?BMC Neuroscience, 2008
- Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathiesProceedings of the National Academy of Sciences, 2007
- A convenient method for regioselective C‐5 halogenation of 4(3H)‐oxo‐7H‐pyrrolo[2,3‐d]pyrimidinesJournal of Heterocyclic Chemistry, 1994